— Know what they know.
Not Investment Advice
Also trades as: 1177.HK (HKSE) · $vol 68M · SBMFF (OTC) · $vol 0M

SBHMY OTC

Sino Biopharmaceutical Limited
1W: +11.5% 1M: +26.9% 3M: +28.4% YTD: -10.7% 1Y: -19.2% 3Y: +140.1% 5Y: +2.0%
$16.28
+1.78 (+12.28%)
 
OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Buy · Power 64 · $14.5B mcap · 438M float · 0.0000% daily turnover · Short 74% of daily vol
Smart Money Score
Watch 0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$14.5B
52W Range11.27-20.16
Volume202
Avg Volume149
Beta0.60
Dividend$0.26
Analyst Ratings
No analyst coverage
Company Info
CEOS. Y. Tse
Employees21,435
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2017-09-05
Unit 09, Office Tower
Hong Kong
HK
852 2802 9886
About Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company. Its operations are organized into three primary divisions: Modernized Chinese and Chemical Medicines, Investment activities, and other varied business ventures. The firm maintains an extensive product range covering numerous therapeutic categories. Among its offerings are oncology treatments, such as Qingkeshu tablets and Leweixin injections; cardiovascular and cerebrovascular medications, including Kaina and Anrixin tablets; hepatitis remedies like Tianqingganmei injections; and orthopedic solutions exemplified by Gaisanchun capsules. The company also produces drugs for respiratory ailments and parenteral nutritional support, for instance, Xinhaineng injections, along with a broad spectrum of other pharmaceutical preparations, such as Tuotuo tablets. Additionally, Sino Biopharmaceutical provides a selection of advanced pharmaceutical agents, including Aprepitant, Lenvatinib Mesilate, Vortioxetine Hydrobromide, and Edaravone injection. Its portfolio also features combination therapies like Amlodipine Besylate and Atorvastatin Calcium, alongside Sofosbuvir, Sitagliptin Phosphate, Colistimethate Sodium for injection, and Tofacitinib Citrate. Beyond its core pharmaceutical manufacturing, the company's diverse business interests encompass property holdings, the retail and distribution of pharmaceutical products, and providing optometry services coupled with the sale of ophthalmic goods. It manages hospitals, delivers medical management and health information consultancy, and offers biotechnology transfer and consultation services. The enterprise is also involved in the production and sale of health foods, provides orthopedic outpatient care and surgical procedures, engages in medical and health technology development, trades optical glasses, and conducts research, development, and commercialization of medical devices and active pharmaceutical ingredients. Established in 2000, the company's corporate headquarters are situated in Wan Chai, Hong Kong.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms